Eureka Therapeutics Stock
Eureka Therapeutics is a biotechnology company focuses on an immunotherapies for the treatment of cancer.
Sign up today and learn more about Eureka Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Eureka Therapeutics Stock
Eureka Therapeutics pursues innovations that will change the world. We develop technologies that advance the field of antibody therapeutics by increasing the efficacy and specificity of antibody drugs, and the expression level of antibody cell lines. Eureka also provides a wide array of contract research services available to other companies. These services center around cell line development and antibody production or purification.
Funding History
| January 2007 | $1K |
|---|---|
| August 2007 | $1.2M |
| November 2008 | $1.7M |
| September 2014 | $21.0M |
| January 2018 | $60.0M |
Management
Research Scientist
Shon Green
Founder, CEO
Cheng Liu
Press
businesswire - Apr, 5 2024
Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ...finance - Apr, 5 2024
Eureka Therapeutics Announces UCSF Benioff Children's Hospitals as First California Site for ARYA-2 Clinical Trial ...prnewswire - Dec, 22 2023
Monoclonal Antibodies: A Transformative Force in ...bioworld - Mar, 17 2023
Eureka Therapeutics licenses antibody targeting mesothelin from NCIEquityZen Recognized As:
